---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-021876"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:42:49.758601+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dyadic licenses fungal platforms to Proliant for recombinant albumin; up to $1.5M milestones + profit share

## Summary
- Dyadic and Proliant Health and Biologicals partner to commercialize animal-free recombinant human serum albumin.
- Dyadic to receive up to $1.5M in milestone payments plus a share of profits from product sales.
- First product launch expected in the first half of 2025, targeting the ~$6B serum albumin market.
- Proliant will use Dyadic's fungal microbial expression platforms for production.

## SEC filing metadata
- accession: 0001437749-24-021876
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774924021876/0001437749-24-021876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774924021876/dyai20240627_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-021876
- JSON: https://secwatch.observer/filing/0001437749-24-021876.json
- Plain text: https://secwatch.observer/filing/0001437749-24-021876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.